Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

August 1, 2026

Conditions

Locally AdvancedHigh-RiskRectal CancerMSS

Interventions

DRUG

Toripalimab

Toripalimab 240mg,d1,q3w

RADIATION

short-term radiotherapy

25Gy/5Fx

DRUG

Oxaliplatin

135mg/m2 d1 q3w

DRUG

Capecitabine

1200mg/m2 d1-14 q3w

Trial Locations (1)

RECRUITING

Nanfang Hospital Southern Medical University, Guangzhou

All Listed Sponsors

collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER